Mr. Speaker, I thank my colleague, because what he talked about is real life. One of the key issues of that question is that the education process is needed.
The other part of it is reporting when there are adverse effects. Right now, basically, the manufacturer and the sponsor are the only ones that are required to do the reporting. When we have medical professionals who acknowledge and see adverse effects that are happening to a patient, they would now have to do that reporting. That is going to be part of the education, at least at the professional level.
The labelling is going to help. We need to make sure that the labelling is also in an educational format, so that families can understand it.